Moors & Cabot’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-1,517
Closed -$245K 922
2025
Q2
$245K Sell
1,517
-4,297
-74% -$684K 0.01% 721
2025
Q1
$989K Sell
5,814
-5,047
-46% -$877K 0.05% 324
2024
Q4
$1.81M Buy
10,861
+1,158
+12% +$198K 0.09% 201
2024
Q3
$1.67M Buy
9,703
+374
+4% +$61.9K 0.08% 217
2024
Q2
$1.44M Buy
9,329
+595
+7% +$89.3K 0.08% 230
2024
Q1
$1.34M Buy
8,734
+365
+4% +$55.7K 0.07% 240
2023
Q4
$1.32M Buy
8,369
+314
+4% +$45.1K 0.08% 234
2023
Q3
$1.18M Buy
8,055
+264
+3% +$40.2K 0.08% 226
2023
Q2
$1.19M Sell
7,791
-81
-1% -$12.6K 0.08% 240
2023
Q1
$1.22M Sell
7,872
-41
-0.5% -$6.44K 0.08% 237
2022
Q4
$1.22M Buy
7,913
+848
+12% +$125K 0.09% 237
2022
Q3
$932K Buy
7,065
+109
+2% +$15.3K 0.07% 266
2022
Q2
$943K Buy
6,956
+795
+13% +$110K 0.07% 283
2022
Q1
$919K Buy
+6,161
New +$911K 0.06% 312
2018
Q2
Sell
-9,062
Closed -$1.2M 570
2018
Q1
$1.2M Buy
9,062
+1,845
+26% +$252K 0.16% 156
2017
Q4
$896K Sell
7,217
-320
-4% -$39.5K 0.12% 201
2017
Q3
$933K Buy
7,537
+167
+2% +$19.8K 0.13% 179
2017
Q2
$841K Buy
7,370
+3,952
+116% +$425K 0.14% 186
2017
Q1
$361K Sell
3,418
-3,195
-48% -$320K 0.06% 344
2016
Q4
$600K Sell
6,613
-441
-6% -$41.3K 0.1% 244
2016
Q3
$703K Sell
7,054
-3,299
-32% -$324K 0.12% 207
2016
Q2
$927K Sell
10,353
-2,046
-17% -$188K 0.16% 156
2016
Q1
$1.09M Sell
12,399
-540
-4% -$47.6K 0.2% 131
2015
Q4
$1.46M Buy
+12,939
New +$1.39M 0.27% 102

Other funds holding FBT

Moors & Cabot's FBT Position: Q3 2025 in Review

Moors & Cabot sold out of First Trust NYSE Arca Biotechnology Index Fund (FBT) in Q3 2025, closing a stake of 1,517 shares — an estimated $245K sold.

Moors & Cabot first reported a position in FBT in Q4 2015 and held it in 24 quarters. The position peaked at $1.81M in Q4 2024. 253 funds tracked by Wall St. Rank hold FBT as of Q3 2025.

  • Moors & Cabot reported no remaining First Trust NYSE Arca Biotechnology Index Fund position as of Q3 2025 after selling out during the quarter.
  • Moors & Cabot sold 1,517 First Trust NYSE Arca Biotechnology Index Fund shares in Q3 2025, an estimated $245K.
  • Moors & Cabot first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q4 2015 and held it in 24 quarters.
  • Moors & Cabot's First Trust NYSE Arca Biotechnology Index Fund position peaked at $1.81M in Q4 2024.
  • 253 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q3 2025.

Based on Moors & Cabot's 13F filing for Q3 2025, filed 14 Nov 2025.